Ibalizumab plus an optimized background regimen in treatment-experienced patients infected with multidrug resistant HIV-1: A phase 3, multicenter, expanded access study

By afschroeder • June 5, 2025

Emu B, Kumar PN, Mills A, Berhe M, Cash BR, Kuo KL, Anstett K. Ibalizumab plus an optimized background regimen in treatment-experienced patients infected with multidrug resistant HIV-1: A phase 3, multicenter, expanded access study. J Acquir Immune Defic Syndr. 2025 Jun 4. doi: 10.1097/QAI.0000000000003699. Epub ahead of print. PMID: 40465394.

Tags: Humanized IgG4 monoclonal antibody, Ibalizumab, Infectious Diseases, Multidrug-resistant human immunodeficiency virus type 1, Optimized background regimen, Publications, Viral entry inhibitor

Universal Bacterium-Vectored COVID-19 Vaccine Expressing Early SARS-CoV-2 Conserved Proteins Cross-Protects Against Late Variants in Hamsters

Jia Q, Bielefeldt-Ohmann H, Masleša-Galić S, Bowen RA, Horwitz MA. Universal Bacterium-Vectored COVID-19 Vaccine Expressing Early SARS-CoV-2 Conserved Proteins Cross-Protects Against Late Variants in Hamsters.[...]

Less is More: A Cost and Environmental Waste Analysis in Nonadherence to Antibiotic Prophylaxis Guidelines in Clean Ambulatory Surgical Procedures

Sandigo-Saballos I, Montero S, Lee P, Lee H, Chen KT. Less is More: A Cost and Environmental Waste Analysis in Nonadherence to Antibiotic Prophylaxis Guidelines[...]

Impact of lifting school mask mandates on community SARS-CoV-2 cases, hospitalizations, and deaths: a retrospective observational study

Ertem Z, Danesharasteh A, Anand ST, Jackson NJ, Nelson RE, Schechter-Perkins EM, Fisher L, Doron S, Branch-Elliman W. Impact of lifting school mask mandates on[...]